Prostate Cancer最新文献_第6页

How Accurately Can Prostate Gland Imaging Measure the Prostate Gland Volume? Results of a Systematic Review. 前列腺成像如何准确测量前列腺体积？系统审查的结果。

IF 2.3

Prostate Cancer Pub Date : 2019-03-03 eCollection Date: 2019-01-01 DOI: 10.1155/2019/6932572

David R H Christie, Christopher F Sharpley

{"title":"How Accurately Can Prostate Gland Imaging Measure the Prostate Gland Volume? Results of a Systematic Review.","authors":"David R H Christie, Christopher F Sharpley","doi":"10.1155/2019/6932572","DOIUrl":"10.1155/2019/6932572","url":null,"abstract":"Aim: The measurement of the volume of the prostate gland can have an influence on many clinical decisions. Various imaging methods have been used to measure it. Our aim was to conduct the first systematic review of their accuracy.Methods: The literature describing the accuracy of imaging methods for measuring the prostate gland volume was systematically reviewed. Articles were included if they compared volume measurements obtained by medical imaging with a reference volume measurement obtained after removal of the gland by radical prostatectomy. Correlation and concordance statistics were summarised.Results: 28 articles describing 7768 patients were identified. The imaging methods were ultrasound, computed tomography, and magnetic resonance imaging (US, CT, and MRI). Wide variations were noted but most articles about US and CT provided correlation coefficients that lay between 0.70 and 0.90, while those describing MRI seemed slightly more accurate at 0.80-0.96. When concordance was reported, it was similar; over- and underestimation of the prostate were variably reported. Most studies showed evidence of at least moderate bias and the quality of the studies was highly variable.Discussion: The reported correlations were moderate to high in strength indicating that imaging is sufficiently accurate when quantitative measurements of prostate gland volume are required. MRI was slightly more accurate than the other methods.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2019 ","pages":"6932572"},"PeriodicalIF":2.3,"publicationDate":"2019-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37290665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States. 第二原发性恶性肿瘤在去势抵抗性前列腺癌患者中的发病率:美国的一项观察性回顾性队列研究。

IF 4.2

Prostate Cancer Pub Date : 2019-02-11 eCollection Date: 2019-01-01 DOI: 10.1155/2019/4387415

Catherine W Saltus, Zdravko P Vassilev, Jihong Zong, Brian Calingaert, Elizabeth B Andrews, Montse Soriano-Gabarró, James A Kaye

{"title":"Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States.","authors":"Catherine W Saltus, Zdravko P Vassilev, Jihong Zong, Brian Calingaert, Elizabeth B Andrews, Montse Soriano-Gabarró, James A Kaye","doi":"10.1155/2019/4387415","DOIUrl":"https://doi.org/10.1155/2019/4387415","url":null,"abstract":"Background: New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with CRPC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. We also estimated the proportion of men with CRPC with bone metastases and overall survival.Methods: We conducted a retrospective cohort study of United States (US) men aged ≥ 65 years with CRPC. Cohort entry was from January 1, 2000, to December 31, 2011, with follow-up through December 31, 2013. Castration resistance was defined by treatment with second-line systemic therapy (after surgical or medical castration). SPM were diagnoses of primary cancers (other than prostate) in SEER or Medicare data.Results: Altogether 2,234 patients met eligibility criteria. Most (1,887; 84.5%) had evidence of bone metastases in Medicare claims. SPM occurred in 172 patients (incidence rate 5.9 per 100 person-years; 95% confidence interval [CI], 5.0-6.8; standardized incidence ratio = 3.1, 95% CI, 2.8-3.6, based on SEER incidence rate of all malignancies except prostate cancer among men aged ≥ 65 years). The most common SPM were lung/bronchus (n = 29, 16.9%), urinary bladder (n = 22, 12.8%), and colon/rectum (n = 21, 12.2%). Median survival was 1.2 years (95% CI, 1.1-1.3); 5-year survival was 9% (95% CI, 7-11%).Conclusions: This study provides the first estimate of SPM risk in older men with CRPC in the US. The incidence rate is approximately threefold higher than the population-based cancer incidence among men without prostate cancer.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2019 ","pages":"4387415"},"PeriodicalIF":4.2,"publicationDate":"2019-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/4387415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37231066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. 诊断性活检前列腺癌患者队列中的预测性 PDE4D7 评分与纵向生物学结果。

IF 4.2

Prostate Cancer Pub Date : 2018-07-26 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5821616

Dianne van Strijp, Christiane de Witz, Pieter C Vos, Eveline den Biezen-Timmermans, Anne van Brussel, Janneke Wrobel, George S Baillie, Pierre Tennstedt, Thorsten Schlomm, Birthe Heitkötter, Sebastian Huss, Martin Bögemann, Miles D Houslay, Chris Bangma, Axel Semjonow, Ralf Hoffmann

{"title":"The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.","authors":"Dianne van Strijp, Christiane de Witz, Pieter C Vos, Eveline den Biezen-Timmermans, Anne van Brussel, Janneke Wrobel, George S Baillie, Pierre Tennstedt, Thorsten Schlomm, Birthe Heitkötter, Sebastian Huss, Martin Bögemann, Miles D Houslay, Chris Bangma, Axel Semjonow, Ralf Hoffmann","doi":"10.1155/2018/5821616","DOIUrl":"10.1155/2018/5821616","url":null,"abstract":"Purpose. To further validate the prognostic power of the biomarker PDE4D7, we investigated the correlation of PDE4D7 scores adjusted for presurgical clinical variables with longitudinal postsurgical biological outcomes. Methods. RNA was extracted from biopsy punches of resected tumors (550 patients; RP cohort) and diagnostic needle biopsies (168 patients; DB cohort). Cox regression and survival were applied to correlate PDE4D7 scores with patient outcomes. Logistic regression was used to combine the clinical CAPRA score with PDE4D7. Results. In univariate analysis, the PDE4D7 score was significantly associated with PSA recurrence after prostatectomy in both studied patient cohorts' analysis (HR 0.53; 95% CI 0.41-0.67; p<1.0E-04 and HR 0.47; 95% CI 0.33-0.65; p<1.0E-04, respectively). After adjustment for the presurgical clinical variables preoperative PSA, PSA density, biopsy Gleason, clinical stage, percentage tumor in the biopsy (data only available for RP cohort), and percentage of positive biopsies, the HR was 0.49 (95% CI 0.38-0.64; p<1.0E-04) and 0.43 (95% CI 0.29-0.63; p<1.0E-04), respectively. The addition of the PDE4D7 to the clinical CAPRA score increased the AUC by 5% over the CAPRA score alone (0.82 versus 0.77; p=0.004). This combination model stratified 14.6% patients of the DB cohort to no risk of biochemical relapse (NPV 100%) over a follow-up period of up to 15 years. Conclusions. The PDE4D7 score provides independent risk information for pretreatment risk stratification. Combining CAPRA with PDE4D7 scores significantly improved the clinical risk stratification before surgery.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2018 ","pages":"5821616"},"PeriodicalIF":4.2,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36431713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far? 转移性前列腺癌的局部治疗:到目前为止有什么证据?

IF 4.2

Prostate Cancer Pub Date : 2018-03-19 eCollection Date: 2018-01-01 DOI: 10.1155/2018/2654572

Pedro Leonel Almeida, Bruno Jorge Pereira

{"title":"Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?","authors":"Pedro Leonel Almeida, Bruno Jorge Pereira","doi":"10.1155/2018/2654572","DOIUrl":"https://doi.org/10.1155/2018/2654572","url":null,"abstract":"Background: Advances in technological, laboratorial, and imaging studies and new treatments available in the last decades significantly improved prostate cancer survival rates. However, this did not occur in metastatic prostate cancer (mPCa) at diagnosis which, in young and fit patients, will become invariably resistant to the established treatments. Progression will lead to an impairment in patients' quality of life and disease-related death.Methods: The authors intend to perform a literature review of the advantages of primary treatment of mPCa. Articles were retrieved and filtered for relevance from PubMed, SciELO, and ScienceDirect until March 2017.Results: Primary treatment is currently indicated only in cases of nonmetastatic PCa. Nonetheless, there might be some benefits in doing local treatment in mPCa in order to control local disease, prevent new metastasis, and improve the efficacy of chemotherapy and hormonotherapy with similar complications rate when compared to locally confined cancer. Independent factors that have a negative influence are age above 70 years, cT4 stage or high-grade disease, PSA ≥ 20 ng/ml, and pelvic lymphadenopathies. The presence of 3 or more of these factors conditions CSS and OS is the same between patients who performed local treatment and those who did not. Metastasis degree and location number can also influence outcome. Meanwhile, patients with visceral metastases have worse results.Conclusions: There is growing evidence supporting local treatment in cases of metastatic prostate cancer at diagnosis in the context of a multimodal approach. However, it should be kept in mind that most of the existing studies are retrospective and it would be important to make consistent prospective studies with well-defined patient selection criteria in order to sustain the existing data and understand the main indications to select patients and perform primary treatment in mPCa.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2018 ","pages":"2654572"},"PeriodicalIF":4.2,"publicationDate":"2018-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/2654572","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36094480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. 阿比特龙和恩杂鲁胺在多西他赛前和后去势抵抗性前列腺癌中的疗效:一项试验水平的荟萃分析。

IF 4.2

Prostate Cancer Pub Date : 2017-01-01 Epub Date: 2017-11-21 DOI: 10.1155/2017/8560827

Mike Fang, Mary Nakazawa, Emmanuel S Antonarakis, Chun Li

{"title":"Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.","authors":"Mike Fang, Mary Nakazawa, Emmanuel S Antonarakis, Chun Li","doi":"10.1155/2017/8560827","DOIUrl":"https://doi.org/10.1155/2017/8560827","url":null,"abstract":"We examined the comparative efficacies of first-line abiraterone and enzalutamide in pre- and postdocetaxel settings in castration-resistant prostate cancer (CRPC) through a trial level meta-analysis. A mixed method approach was applied to 19 unique studies containing 17 median overall survival (OS) estimates and 13 median radiographic progression-free survival (PFS) estimates. We employed a random-effects meta-analysis to compare efficacies of abiraterone and enzalutamide with respect to OS and PFS. In the predocetaxel setting, enzalutamide use was associated with an increase in median OS of 5.9 months (p < 0.001), hazard ratio (HR) = 0.81, and an increase in median PFS of 8.3 months (p < 0.001), HR = 0.47 compared to abiraterone. The advantage of enzalutamide improved after adjusting for baseline Gleason score to 19.5 months (p < 0.001) and 14.6 months (p < 0.001) in median OS and PFS, respectively. In the postdocetaxel setting, the advantage of enzalutamide use was nominally significant for median PFS (1.2 months p = 0.02 without adjustment and 2.2 months and p = 0.0007 after adjustment); there was no significant difference in median OS between the two agents. The results from this comprehensive meta-analysis suggest a survival advantage with the use of first-line enzalutamide over abiraterone in CRPC and highlight the need for prospective clinical trials.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2017 ","pages":"8560827"},"PeriodicalIF":4.2,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/8560827","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35759335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

The Single-Knot Running Vesicourethral Anastomosis after Minimally Invasive Prostatectomy: Review of the Technique and Its Modifications, Tips, and Pitfalls. 微创前列腺切除术后膀胱尿道单结吻合术:技术综述及其改进、提示和缺陷。

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-05-31 DOI: 10.1155/2016/1481727

Simone Albisinni, Fouad Aoun, Alexandre Peltier, Roland van Velthoven

引用次数: 13

Systematic Review of Focal Prostate Brachytherapy and the Future Implementation of Image-Guided Prostate HDR Brachytherapy Using MR-Ultrasound Fusion. 聚焦前列腺近距离治疗的系统性综述和使用磁共振-超声波融合的图像引导前列腺 HDR 近距离治疗的未来实施。

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-05-16 DOI: 10.1155/2016/4754031

M Sean Peach, Daniel M Trifiletti, Bruce Libby

{"title":"Systematic Review of Focal Prostate Brachytherapy and the Future Implementation of Image-Guided Prostate HDR Brachytherapy Using MR-Ultrasound Fusion.","authors":"M Sean Peach, Daniel M Trifiletti, Bruce Libby","doi":"10.1155/2016/4754031","DOIUrl":"10.1155/2016/4754031","url":null,"abstract":"Prostate cancer is the most common malignancy found in North American and European men and the second most common cause of cancer related death. Since the practice of PSA screening has become common the disease is most often found early and can have a long indolent course. Current definitive therapy treats the whole gland but has considerable long-term side effects. Focal therapies may be able to target the cancer while decreasing dose to organs at risk. Our objective was to determine if focal prostate brachytherapy could meet target objectives while permitting a decrease in dose to organs at risk in a way that would allow future salvage treatments. Further, we wanted to determine if focal treatment results in less toxicity. Utilizing the Medline repository, dosimetric papers comparing whole gland to partial gland brachytherapy and clinical papers that reported toxicity of focal brachytherapy were selected. A total of 9 dosimetric and 6 clinical papers met these inclusion criteria. Together, these manuscripts suggest that focal brachytherapy may be employed to decrease dose to organs at risk with decreased toxicity. Of current technology, image-guided HDR brachytherapy using MRI registered to transrectal ultrasound offers the flexibility and efficiency to achieve such focal treatments. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2016 ","pages":"4754031"},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34636610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy. 原发性近距离治疗后生化复发前列腺癌的补救性近距离治疗。

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-03-22 DOI: 10.1155/2016/9561494

John M Lacy, William A Wilson, Raevti Bole, Li Chen, Ali S Meigooni, Randall G Rowland, William H St Clair

{"title":"Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy.","authors":"John M Lacy, William A Wilson, Raevti Bole, Li Chen, Ali S Meigooni, Randall G Rowland, William H St Clair","doi":"10.1155/2016/9561494","DOIUrl":"https://doi.org/10.1155/2016/9561494","url":null,"abstract":"Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41-1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2016 ","pages":"9561494"},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/9561494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34413291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Advances in Radiotherapy for Prostate Cancer Treatment. 前列腺癌放疗治疗进展。

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-07-25 DOI: 10.1155/2016/3079684

Tarun Podder, Daniel Song, Timothy Showalter, Luc Beaulieu

{"title":"Advances in Radiotherapy for Prostate Cancer Treatment.","authors":"Tarun Podder, Daniel Song, Timothy Showalter, Luc Beaulieu","doi":"10.1155/2016/3079684","DOIUrl":"https://doi.org/10.1155/2016/3079684","url":null,"abstract":"Major categories of radiotherapy (RT) for prostate cancer (CaP) treatment are: (1) external beam RT (EBRT), and (2) brachytherapy (BT). EBRT are performed using different techniques like three-dimensional conformal RT (3D-CRT), intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated proton therapy (IMPT), etc., using a variety of radiation delivery machines, such as a linear accelerator (Linac), Cyberknife robotic system, Gamma knife, Tomotherapy and proton beam machine. The primary advantage of proton beam therapy is sparing of normal tissues and organ at risks (OARs) with comparable coverage of the tumor volume. MR-Linac is the latest addition in the image-guided RT. Robot-assisted brachytherapy is one of the latest technological innovations in the field. With the advancement of technology, radiation therapy for prostate cancer can be improved using high quality multimodal imaging, robot-assistance for brachytherapy as well as EBRT. This chapter presents the advances in radiation therapy for the treatment of prostate cancer.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2016 ","pages":"3079684"},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/3079684","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34307458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. 磁共振成像/超声融合引导前列腺活检与24核经会阴模板饱和定位前列腺活检联合靶向加系统活检方法的性能评估

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-05-16 DOI: 10.1155/2016/3794738

Francis Ting, Pim J Van Leeuwen, James Thompson, Ron Shnier, Daniel Moses, Warick Delprado, Phillip D Stricker

{"title":"Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy.","authors":"Francis Ting, Pim J Van Leeuwen, James Thompson, Ron Shnier, Daniel Moses, Warick Delprado, Phillip D Stricker","doi":"10.1155/2016/3794738","DOIUrl":"https://doi.org/10.1155/2016/3794738","url":null,"abstract":"Objective. To compare the performance of multiparametric resonance imaging/ultrasound fusion targeted biopsy (MRI/US-TBx) to a combined biopsy strategy (MRI/US-TBx plus 24-core transperineal template saturation mapping biopsy (TTMB)). Methods. Between May 2012 and October 2015, all patients undergoing MRI/US-TBx at our institution were included for analysis. Patients underwent MRI/US-TBx of suspicious lesions detected on multiparametric MRI +/- simultaneous TTMB. Subgroup analysis was performed on patients undergoing simultaneous MRI/US-TBx + TTMB. Primary outcome was PCa detection. Significant PCa was defined as ≥Gleason score (GS) 3 + 4 = 7 PCa. McNemar's test was used to compare detection rates between MRI/US-TBx and the combined biopsy strategy. Results. 148 patients underwent MRI/US-TBx and 80 patients underwent MRI/US-TBx + TTMB. In the MRI/US-TBx versus combined biopsy strategy subgroup analysis (n = 80), there were 55 PCa and 38 significant PCa. The detection rate for the combined biopsy strategy versus MRI/US-TBx for significant PCa was 49% versus 40% (p = 0.02) and for insignificant PCa was 20% versus 10% (p = 0.04), respectively. Eleven cases (14%) of significant PCa were detected exclusively on MRI/US-TBx and 7 cases (8.7%) of significant PCa were detected exclusively on TTMB. Conclusions. A combined biopsy approach (MRI/US-TBx + TTMB) detects more significant PCa than MRI/US-TBx alone; however, it will double the detection rate of insignificant PCa. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2016 ","pages":"3794738"},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/3794738","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34636609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15